Literature DB >> 8959957

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.

S Tseng1, G Pak, K Washenik, M K Pomeranz, J L Shupack.   

Abstract

Thalidomide, a hypnosedative drug introduced in the 1950s, has been used in a variety of dermatologic conditions during the past few decades. Although originally withdrawn from the world market on discovery of its teratogenic effect, it has since been selectively reintroduced for use in various disorders thought to have an autoimmune or inflammatory basis. A review of the literature focused on clinical uses of thalidomide in the treatment of dermatologic diseases was performed. Diseases for which thalidomide has been found effective include erythema nodosum leprosum, prurigo nodularis, actinic prurigo, discoid lupus erythematosus, aphthous stomatitis, Behçet's syndrome, and graft-versus-host disease. Side effects such as teratogenicity and peripheral neuropathy remain its limiting factor. Thalidomide is a useful addition to the therapeutic armamentarium for treatment-resistant dermatoses as long as proper vigilance for adverse effects is maintained.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959957     DOI: 10.1016/s0190-9622(96)90122-x

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  42 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice.

Authors:  Jean Marie B. Ruddy; Shyamal K. Majumdar
Journal:  J Biomed Biotechnol       Date:  2002

Review 3.  [Hereditary photodermatoses].

Authors:  P Poblete-Gutiérrez; W H C Burgdorf; C Has; M Berneburg; J Frank
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

Review 4.  What can we learn from the thalidomide experience: an ophthalmologic perspective.

Authors:  Marilyn T Miller; Kerstin K Strömland
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

Review 5.  Cutaneous Lupus Erythematosus: Progress and Challenges.

Authors:  Amy J Petty; Lauren Floyd; Christopher Henderson; Matilda W Nicholas
Journal:  Curr Allergy Asthma Rep       Date:  2020-04-04       Impact factor: 4.806

6.  Latanoprost-induced changes in rat intraocular pressure: direct or indirect?

Authors:  Shahid Husain; Phillip W Yates; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

7.  Do Wortmannin and Thalidomide induce apoptosis by autophagy inhibition in 4T1 breast cancer cells in vitro and in vivo?

Authors:  Elgin Turkoz Uluer; Pinar Kilicaslan Sonmez; Damla Akogullari; Melike Onal; Gamze Tanriover; Sevinc Inan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity.

Authors:  Ronen Rabinowitz; Gabriel Katz; Mordechai Rosner; Sara Pri-Chen; Abraham Spierer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-03-15       Impact factor: 3.117

Review 9.  Thalidomide analogues as anticancer drugs.

Authors:  Jeanny B Aragon-Ching; Haiqing Li; Erin R Gardner; William D Figg
Journal:  Recent Pat Anticancer Drug Discov       Date:  2007-06       Impact factor: 4.169

Review 10.  Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.

Authors:  Antonio Palumbo; Carmela Palladino
Journal:  Ther Adv Drug Saf       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.